More News

11 June 2018

Alexion and Complement Pharma Announce Partnership to Co-Develop Pre-Clinical Complement Inhibitor for Neurodegenerative Disorders

11 June 2018

Translate Bio Announces Agreement with Sanofi Pasteur to Develop Vaccines for Infectious Diseases using Novel mRNA Technology

8 June 2018

Ophthotech Enters into Gene Therapy Agreements with the University of Florida and the University of Pennsylvania

8 June 2018

Biogen Enters Exclusive Option Agreement to Acquire TMS’ Phase 2 Asset for Acute Stroke

6 June 2018

Microbiotica Enters into Microbiome Collaboration with Genentech

6 June 2018

Ionis Closes Strategic Collaboration with Biogen to Develop Drugs for a Broad Range of Neurological Diseases

5 June 2018

Hookipa and Gilead Enter into a Collaboration and License Agreement to Develop Immunotherapies Against HIV and Hepatitis B

4 June 2018

Versartis Enters into Merger Agreement with Aravive Biologics to Form a Clinical-Stage Biopharmaceutical Company Advancing Innovative Oncology Therapeutics

4 June 2018

Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China

2 June 2018

MolMed and Glycostem announce the execution of a binding term sheet for the development and manufacturing of allogeneic CAR-NK therapies

2 June 2018

Nerviano Medical Sciences announces Collaboration and License Agreement with Merck to discover small molecule inhibitors of certain anticancer targets

1 June 2018

Amgen And MD Anderson Announce Collaboration To Accelerate Early Stage Treatments For Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, Small-Cell Lung And Other Small-Cell Cancers

1 June 2018

Bayer and MD Anderson Cancer Center Collaborate to Strengthen Oncology Translational Research and Clinical Development

31 May 2018

F-star Announces Early Exercise by Denali Therapeutics of its Option to Acquire F-star Gamma

31 May 2018

Celltrion and Yonsei University Health System Team up to Develop New Drugs for Cerebrovascular Diseases

31 May 2018

ASKA and Takeda Enter into Licensing Agreement for Relugolix in Women’s Health Indications

30 May 2018

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

30 May 2018

Casma Therapeutics Co-Founder Reports Health Benefits of Increased Autophagy in Mammals in Nature Publication

29 May 2018

CERENIS Therapeutics and University of North Texas Health Science Center Announce a Strategic Initiative to Develop New HDL-Based Pharmaceutical Products

25 May 2018

Bicycle Therapeutics Expands Strategic Partnership with AstraZeneca

24 May 2018

San Diego-based Epigen Biosciences enters a collaboration to license its LPA1 Receptor small molecule program to Novo Nordisk A/S for up to USD 200 Million

23 May 2018

mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States

23 May 2018

Monarch Biosciences Announces Fred Hutch Exclusive License and Presentations at BIO Regarding Cell Therapy Delivery Technology

23 May 2018

VFMCRP and Cara Therapeutics to develop and commercialise CR845 injection for chronic kidney disease-associated pruritus

23 May 2018

Evotec and Celgene enter into strategic oncology partnership

22 May 2018

Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research Collaboration

22 May 2018

Karo Pharma receives milestone payment for RORgamma

18 May 2018

Accent Therapeutics Announces Company Launch with $40 Million Series A Financing for Novel, Precision Cancer Treatments Targeting RNA-Modifying Proteins

17 May 2018

Intellia Therapeutics Announces WT1 as Its First Cell Therapy Target, Following Presentation of Early Data at the American Society of Gene and Cell Therapy 21st Annual Meeting

16 May 2018

Fate Therapeutics and Memorial Sloan Kettering Cancer Center Expand Scope of License Agreement to include Gene-edited T-cell Immunotherapies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

Bispecific Antibodies for Immuno-Oncology & Other Diseases

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

Ustekinumab (Stelara) Biosimilars Pipeline Review

Report Package: “Drug the Undruggable” Technologies

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

TROP-2-Targeted Immunotherapy Pipeline Review